$3.32
5.68% yesterday
Nasdaq, Jun 13, 10:00 pm CET
ISIN
US74365N1037
Symbol
PTIX

Protagenic Therapeutics Inc Stock price

$3.32
-0.19 5.41% 1M
-3.61 52.09% 6M
-3.54 51.60% YTD
-9.66 74.42% 1Y
-61.08 94.84% 5Y
-949.26 99.65% 10Y
-311,754,236.68 100.00% 20Y
Nasdaq, Closing price Fri, Jun 13 2025
-0.20 5.68%
ISIN
US74365N1037
Symbol
PTIX

Key metrics

Market capitalization $2.88m
Enterprise Value $2.01m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio negative
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-5.33m
Free Cash Flow (TTM) Free Cash Flow $-3.63m
Cash position $870.00k
EPS (TTM) EPS $-10.01
Short interest 5.61%
Show more

Is Protagenic Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,847 stocks worldwide.

Financial data from Protagenic Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 2.05 2.05
86% 86%
-
- Research and Development Expense 3.36 3.36
24% 24%
-
-5.28 -5.28
4% 4%
-
- Depreciation and Amortization 0.05 0.05
25% 25%
-
EBIT (Operating Income) EBIT -5.33 -5.33
3% 3%
-
Net Profit -5.24 -5.24
13% 13%
-

In millions USD.

Don't miss a Thing! We will send you all news about Protagenic Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Protagenic Therapeutics Inc Stock News

Neutral
Accesswire
24 days ago
NEW YORK, NY / ACCESS Newswire / May 21, 2025 / Protagenic Therapeutics, Inc. (Nasdaq:PTIX) (the "Company") announced today that warrant exchanges and exercises over the last four trading days have generated $3.1 million in cash. The proceeds will fund working-capital needs and advance the Company's peptide-based drug candidates for stress-related and central-nervous-system disorders.
Neutral
Business Wire
26 days ago
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Protagenic Therapeutics, Inc. (NASDAQ: PTIX) and Phytanix Bio Inc. is fair to Protagenic shareholders. Upon completion of the proposed transaction, Protagenic shareholders are expected to own approximately 35% of the combined company. Halper Sadeh encourages Protagenic shareholders t...
Neutral
Accesswire
26 days ago
NEW YORK, NY AND SANTA BARBARA, CA / ACCESS Newswire / May 19, 2025 / Protagenic Therapeutics, Inc. (Nasdaq:PTIX) (the "Company") and Phytanix Bio Inc. have entered into a definitive share exchange agreement pursuant to which the two entities will combine in an all-stock transaction (the "Combination"). The combined entity, to be called Phytanix, Inc., will bring together two pipelines focused ...
More Protagenic Therapeutics Inc News

Company Profile

Protagenic Therapeutics, Inc. is a biotechnology company, which engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. It offers the PT00114 peptide-based formulations. The company was founded by Garo H. Armen, David A. Lovejoy, and Hartoun Hartounian on February 3, 1994 and is headquartered in New York, NY.

Head office United States
Employees 2
Founded 1994
Website protagenic.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today